Keyphrases
Chemokine CXCL13
100%
Tumefactive multiple Sclerosis
100%
CXCL13
100%
Cerebrospinal Fluid Concentration
100%
Multiple Sclerosis
80%
CSF Concentration
80%
B Cells
80%
Natalizumab
60%
Clinically Isolated Syndrome
60%
Relapsing-remitting MS
60%
Disease Activity
40%
CXCR5
40%
Progressive multiple Sclerosis
40%
Progressive MS
40%
Methylprednisolone
40%
Control Subjects
20%
Blood Samples
20%
Treatment Effect
20%
Interleukin-10
20%
T Helper 1
20%
Neurological Diseases
20%
T Cell Subsets
20%
Relapsing-remitting multiple Sclerosis
20%
Transforming Growth factor-β1 (TGF-β1)
20%
T Helper 17 (Th17)
20%
Chemokines
20%
Noninflammatory
20%
CSF B Cells
20%
Low Expression
20%
Cell-to-cell
20%
Evidence Support
20%
Cell Count
20%
Chemokine Receptor
20%
Chemokine Ligand 12 (CXCL12)
20%
Disease Control
20%
Immune Activation
20%
Immunosuppressive Cytokines
20%
Therapeutic Target
20%
High-dose Methylprednisolone
20%
Multiple Sclerosis Pathogenesis
20%
Messenger RNA (mRNA)
20%
Immunology and Microbiology
Cerebrospinal Fluid
100%
CXCL13 Chemokine
100%
Multiple Sclerosis
100%
CXCL13
83%
B Cell
83%
Methylprednisolone
50%
Clinically Isolated Syndrome
50%
Natalizumab
50%
Chemokine Receptor CXCR5
33%
Cytokine
16%
Transforming Growth Factor Beta1
16%
Secondary Progressive Multiple Sclerosis
16%
Primary Progressive Multiple Sclerosis
16%
Relapsing Remitting Multiple Sclerosis
16%
Cell Count
16%
Drug Megadose
16%
Chemokine
16%
Interleukin 10
16%
T Cell Subset
16%
Neuroscience
Multiple Sclerosis
100%
CXCL13 Chemokine
100%
B Cell
83%
CXCL13
83%
Natalizumab
50%
Demyelinating Disease
50%
Methylprednisolone
50%
Chemokine Receptor CXCR5
33%
Chemokine
16%
Interleukin 10
16%
Primary Progressive Multiple Sclerosis
16%
Secondary Progressive Multiple Sclerosis
16%
Relapsing Remitting Multiple Sclerosis
16%
Nervous System Disorder
16%
Transforming Growth Factor Beta1
16%
T Cell
16%